Schering-Plough Drug Gets Fast Track (Chronic Hepatitis C)

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership
Genetic Engineering News - Inovio Biomedical Corporation (AMEX:INO), a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has signed an agreement with Swedish-based Tripep AB (The Stockholm

First-Time Generic Approvals: Copegus, Tegretol, Roxicodone
Medscape News - Jan. 24, 2006 The US Food and Drug Administration (FDA) approved in December 2005 first-time generic 200-mg formulations of ribavirin and carbamazepine tablets, and 15- and 30-mg formulations of oxycodone HCl tablets. First-time doses (ie, no